alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit31.1**

**CERTIFICATIONOF PRINCIPAL EXECUTIVE OFFICER**

I, Michael N. Chang,certify that:

1. I have reviewed this quarterly report on Form 10-Q of OptimerPharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)    designed such disclosure controls andprocedures, or caused such disclosure controls and procedures to be designedunder our supervision, to ensure that material information relating to theregistrant, including any consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which thisreport is being prepared;

b)    evaluated the effectiveness of theregistrant’s disclosure controls and procedures and presented in this reportour conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on suchevaluation; and

c)    disclosed in this report any change in theregistrant’s internal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarterin the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financialreporting; and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalent functions):

a)    all significant deficiencies and materialweaknesses in the design or operation of internal control over financialreporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial information; and

b)    any fraud, whether or not material, thatinvolves management or other employees who have a significant role in theregistrant’s internal control over financial reporting.
| Date: August 10,  2007                 |
|----------------------------------------|
|                                   |
| /s/ Michael N. Chang                   |   |
| Michael N. Chang                       |
| President and  Chief Executive Officer |

 

----
I 

115TH CONGRESS 

2D SESSION H. R. 4864 

To amend title 18, United States Code, to penalize unlawful flight to avoid 

prosecution into or from Indian country. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 19, 2018 

Mrs. NOEM (for herself and Mr. GOWDY) introduced the following bill; which 

was referred to the Committee on the Judiciary, and in addition to the 

Committee on Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions 

as fall within the jurisdiction of the committee concerned 

A BILL 

To amend title 18, United States Code, to penalize unlawful 

flight to avoid prosecution into or from Indian country. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘No Haven for Dan5 gerous Fugitives Act of 2018’’. 

6 SEC. 2. FLIGHT TO AVOID PROSECUTION OR GIVING TESTI7 MONY. 

8 Section 1073 of title 18, United States Code, is 

9 amended by inserting after ‘‘Whoever moves or travels in 


ethrower on DSK3G9T082PROD with BILLS
2 

•HR 4864 IH

1 interstate or foreign commerce’’ the following: ‘‘or is 

2 present within the special maritime and territorial juris3 diction of the United States, or enters or leaves Indian 

4 country (as such term is defined in section 1151),’’. 

5 SEC. 3. SENSE OF CONGRESS. 

6 It is the sense of Congress that Federal, State, and 

7 local governments should respect Tribal sovereignty at all 

8 times, including by engaging in all reasonable efforts to 

9 reach extradition agreements with Indian Tribes. 

Æ 


ethrower on DSK3G9T082PROD with BILLS
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[S. 1656 Introduced in Senate (IS)]

104th CONGRESS
  2d Session
                                S. 1656

  To permit individuals to continue health plan coverage of services 
           while participating in approved clinical studies.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             March 29, 1996

   Ms. Snowe introduced the following bill; which was read twice and 
         referred to the Committee on Labor and Human Resources

_______________________________________________________________________

                                 A BILL

 
  To permit individuals to continue health plan coverage of services 
           while participating in approved clinical studies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Improved Patient Access to Clinical 
Studies Act of 1996''.

SEC. 2. COVERAGE FOR INDIVIDUALS PARTICIPATING IN APPROVED CLINICAL 
              STUDIES.

    (a) Permitting Participation in Approved Clinical Studies.--A 
health plan may not deny (or limit or impose additional conditions on) 
coverage of items and services furnished to an enrollee if--
            (1) the enrollee is participating in an approved clinical 
        study,
            (2) the items and services are furnished according to the 
        design of the study or to treat conditions resulting from 
        participation in the study, and
            (3) the items and services would otherwise be covered under 
        the plan except for the fact that they are provided in 
        connection with participation in such a study.
A health plan may not discriminate against an enrollee on the basis of 
the enrollee's participation in such a study.
    (b) Construction.--Nothing in subsection (a) shall be construed as 
requiring a health plan to provide for payment for items and services 
normally paid for as part of an approved clinical study.
    (c) Approved Clinical Study Defined.--In this section, the term 
``approved clinical study'' means--
            (1) a research study approved by the Secretary of Health 
        and Human Services, the Director of the National Institutes of 
        Health, the Commissioner of the Food and Drug Administration, 
        the Secretary of Veterans Affairs, the Secretary of Defense, or 
        a qualified nongovernmental research entity (as defined in 
        guidelines of the National Institutes of Health), or
            (2) a peer-reviewed and approved research program, as 
        defined by the Secretary of Health and Human Services, 
        conducted for the primary purpose of determining whether or not 
        a treatment is safe, efficacious, or having any other 
        characteristic of a treatment which must be demonstrated in 
        order for the treatment to be medically necessary or 
        appropriate.
                                 <all>
```
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Defense Acquisition Regulations System

          - 48 CFR Parts 245 and 225
          - [Docket DARS-2024-0001]

# AGENCY:

Defense Acquisition Regulations System, Department of Defense (DoD).

# ACTION:

Final rule; technical amendment.

# SUMMARY:

DoD is amending the Defense Federal Acquisition Regulation Supplement (DFARS) to make needed editorial changes.

# DATES:

Effective February 15, 2024.

# FOR FURTHER INFORMATION CONTACT:

Ms. Jennifer D. Johnson, Defense Acquisition Regulations System, telephone 703-717-8226.

# SUPPLEMENTARY INFORMATION:

 This final rule amends the DFARS to make needed editorial changes to update an outdated office name and address at DFARS 245.102 and to correct typographical errors at DFARS 252.223-7009.

# List of Subjects in 48 CFR Parts 245 and 252

      - Government procurement

Jennifer D. Johnson,

Editor/Publisher, Defense Acquisition Regulations System.

Therefore, 48 CFR parts 245 and 252 are amended as follows:

1. The authority citation for 48 CFR parts 245 and 252 continues to read as follows:

Authority: 41 U.S.C. 1303 and 48 CFR chapter 1.

# PART 245—GOVERNMENT PROPERTY

2. Amend section 245.102 by revising paragraph (4)(ii)(C)( *2*) to read as follows:                    

245.102 

* * * * *

(4) * * *

(ii) * * *

(C) * * *

                            (2) A copy of the executed determination and findings shall be provided to the Office of the Principal Director, Defense Pricing and Contracting (DPC) (Contracting eBusiness) via email at                             *osd.pentagon.ousd-a-s.mbx.dpc-cb@mail.mil.*

# PART 252—SOLICITATION PROVISIONS AND CONTRACT CLAUSES

3. Amend section 252.223-7009 by revising the clause title and date to read as follows: 

252.223-7009 

* * * * *

## Prohibition of Procurement of Fluorinated Aqueous Film-Forming Foam Fire-Fighting Agent for Use on Military Installations (Feb 2024)

* * * * *

[FR Doc. 2024-01221 Filed 2-14-24; 8:45 am]

BILLING CODE 6001-FR-P
CERTIFICATIONS

I, James B. Hovis, certify that:

1. I have reviewed this Annual Report on Form 10-KSB of Phlo Corporation and
Affiliates;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a. designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this report is being prepared;

b. evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this report
(the "Evaluation Date"); and

c. presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):

a. all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b. any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
report whether there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date
of our most recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.

Date: July 8, 2005

                                /s/ James B. Hovis
                                ---------------------------
                                James B. Hovis
                                Chief Executive Officer
                                Principal Financial Officer
**EXHIBIT
      99.2**





**Certification
      Pursuant to 18 U.S.C. Section 1350 As Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002**








I,
      Adam
      Mauerberger, President and Chief Financial Officer of Atlantic Wine Agencies
      Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley
      Act
      of 2002, 18 U.S.C. Section 1350, that:





(1)  the
      Quarterly Report on Form 10-QSB of the Company for the quarter ended December
      31, 2006 (the "Report") fully complies with the requirements of Section 13(a)
      or
      15(d) of the Securities Exchange Act of 1934, as amended; and





(2)  the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.








Date:
      February 21, 2007








/s/
      Adam Mauerberger


Adam
      Mauerberger


President
      and Chief Financial Officer
Docket No. FAA

− 2015

− 3544

Frederick H. Meek

6848 Sundrop Street

Harmony, FL 34773

(407)902

- 7100

M rfhm @aol.com

In response to email dated 11/12/15 regarding machine specifics:

Flight Machine Specifics :

Leptron RDASS 1000 , Manufactured by Leptron in Denver, CO.

Weight 7.1 lbs (including payload)

Rotorcraft Propulsion (Quadcopter)

DJI Phantom 3 Professional, Manufactured by DJI

Weight 2.822 lbs (i ncluding battery/camera/propelle rs)

Rotorcraft Propulsio n (Quadcopter)

DJI Phantom 2 Vision Plus (+) , Manufactured by DJI

Weight 2.738 lbs (including battery/camera/propellers)
**CERTIFICATION      OF STEPHEN W. CARNES**

**PURSUANT      TO SECTION 906 OF THE SARBANES-OXLEY ACT**

**CERTIFICATION      PURSUANT TO **

**SECTION      906 OF THE SARBANES-OXLEY ACT OF 2002 **

| 1. | The                Report fully complies with the requirements of Section 13(a) or 15(d)                of                the Securities Exchange Act of 1934;                and |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| /s/                Stephen W.                Carnes                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Stephen                W. Carnes                                                                                                                                                                                                  |
| Chief                Executive Officer and                                                                                                                                                                                        |
| Principal                Accounting Officer                                                                                                                                                                                       |

----
##### 



Exhibit 3.1
 AMENDED AND RESTATED BY-LAWS
OF VALEANT PHARMACEUTICALS INTERNATIONAL
(a Delaware corporation and hereinafter called the Corporation)
 ARTICLE I
 Offices
 Registered Office
 Other Offices
 ARTICLE II
 Meetings of Stockholders
 Place of Meetings
 Annual Meeting
 Special Meetings
 Notice of Meetings
 1.




---



##### 



List of Stockholders
 Quorum, Adjournments
 Organization
 Order of Business
 Voting
 2.




---



##### 



Inspectors
 No Action by Consent
 3.




---



##### 



ARTICLE III
 Board of Directors
 General Powers
 Number, Classes, Qualifications, Election and Term of Office.
    4.




---



##### 



Place of Meetings
 5.




---



##### 



Annual Meeting
 Regular Meetings
 Special Meetings
 Notice of Meetings
 Quorum and Manner of Acting
 6.




---



##### 



Organization
 Resignations
 Vacancies
 Removal of Directors
 Compensation
 Committees
 7.




---



##### 



Action by Consent
 Meetings by Electronic Communications Equipment
 ARTICLE IV
 Officers
 Officers
 Resignations
 Removal
 8.




---



##### 



The Chairman of the Board
 The Chief Executive Officer
 The President
 The Vice-President
 The Treasurer
 The Secretary
 9.




---



##### 



The Assistant Treasurer
 The Assistant Secretary
 Additional Officers
 Officers Bonds or Other Security
 Compensation
 ARTICLE V
 Stock Certificates and their Transfer
 Stock Certificates and Uncertificated Shares
 10.




---



##### 



Facsimile Signatures
 Lost Certificates
 Transfers of Stock
 11.




---



##### 



Transfer Agents and Registrars
 Regulations
 Fixing the Record Date
 Registered Stockholders
 ARTICLE VI
 Indemnification of Directors and Officers
 General
 12.




---



##### 



Derivative Actions
 Indemnification in Certain Cases
 Procedure
 Advances for Expenses
 13.




---



##### 



Rights Not-Exclusive
 Insurance
 Definition of Corporation
 Survival of Rights
 ARTICLE VII
 General Provisions
 Dividends
 Reserves
 14.




---



##### 



Seal
 Fiscal Year
 Checks, Notes, Drafts, Etc
 Execution of Contracts, Deeds, Etc
 Voting Upon Stocks
 ARTICLE VIII
 Amendments
  15.
II

104TH CONGRESS

2D SESSION S. 1591

To prohibit campaign expenditures for services of lobbyists, and for other

purposes.

IN THE SENATE OF THE UNITED STATES

MARCH 6, 1996

Mr. MCCAIN introduced the following bill; which was read twice and referred

to the Committee on Rules and Administration

A BILL

To prohibit campaign expenditures for services of lobbyists,

and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. AMENDMENT OF FECA.

4 (a) IN GENERAL.—Section 315 of the Federal Elec5 tion Campaign Act of 1971 (2 U.S.C. 441a) is amended

6 by adding at the end the following new subsection:

7 ‘‘(i) Notwithstanding any other provision of this Act,

8 a candidate and the candidate’s authorized committees

9 shall not make disbursements for any services rendered

10 by, any individual if such individual, was required to reg-
2

•S 1591 IS

1 ister as a lobbyist under the Lobbying Disclosure Act of

2 1995 (2 U.S.C. 1601 et seq.).’’.

3 (b) REPORTING.—Section 304(b) of the Federal

4 Election Campaign Act of 1971 (2 U.S.C. 434(b)) is

5 amended—

6 (1) in paragraph (7), by striking ‘‘and’’ after

7 the semicolon;

8 (2) in paragraph (8), by striking the period at

9 the end and inserting ‘‘; and’’; and

10 (3) by adding at the end the following new

11 paragraph:

12 ‘‘(9) for an authorized committee, an identifica13 tion, including the name and address, of any lobbyist

14 (as that term is defined in section 3 of the Lobbying

15 Disclosure Act of 1995 (2 U.S.C. 1602)) who pro16 vided services to the authorized committee, regard17 less of whether disbursements were made for such

18 services.’’.

19 SEC. 2. AMENDMENT OF LOBBYING DISCLOSURE ACT OF

20 1995.

21 Section 5(b) of the Lobbying Disclosure Act of 1995

22 (2 U.S.C. 1604(b)) is amended—

23 (1) in paragraph (3), by striking ‘‘and’’ after

24 the semicolon;
3

•S 1591 IS

1 (2) in paragraph (4), by striking the period at

2 the end and inserting ‘‘; and’’; and

3 (3) by adding at the end the following new

4 paragraph:

5 ‘‘(5) the amount and date of each contribution

6 by the registrant to a candidate, or an authorized

7 committee (as that term is defined in section 301 of

8 the Federal Election Campaign Act of 1971 (2

9 U.S.C. 431)) of a candidate, for the office of Sen10 ator or Representative in, or Delegate or Resident

11 Commissioner to, the Congress.’’.

Æ
I

104TH CONGRESS

2D SESSION S. 1834

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 4, 1996

Referred to the Committee on Resources

AN ACT

To reauthorize the Indian Environmental General Assistance

Program Act of 1992, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
2

S 1834 RFH

1 SECTION 1. REAUTHORIZATION.

2 Section 502(h) of the Indian Environmental General

3 Assistance Program Act of 1992 (42 U.S.C. 4368b(h)) is

4 amended by striking ‘‘$15,000,000’’ and inserting ‘‘such

5 sums as may be necessary’’.

Passed the Senate August 2, 1996.

Attest: KELLY D. JOHNSTON,

Secretary.